Dr. Sashi Kant Singh

OPD Schedule

Educational Qualifications

• MBBS from Christian Medical College, Vellore
• MD General Medicine from All India Institute of Medical Sciences, New Delhi
• DM Clinical Hematology from All India Institute of Medical Sciences, Rishikesh

Work Experience

• Worked as a Senior Resident, Medicine in All India Institute of Medical Sciences, New Delhi
• Associate Consultant, Hematology and BMT, Artemis Hospital, Gurugram
• Associate Consultant, Hematology and BMT, Indraprastha Apollo,New Delhi

Publications

• Sashi Kant Singh, Karthik Kumar ,Uttam Kumar Nath et al ;
  Comparison of Generic Dasatinib Versus Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia with Reference to Early Molecular Response: Results from a Single-Center, Randomized Controlled Study from India.
  Blood 2022; 9640–9642. doi: https://doi.org/10.1182/blood-2022-158786
• Paras Satadeve, Sashi Singh, Adamya Gupta et al -World Data of Molecular Response Using Different Dosage of Upfront Generic Dasatinib in Chronic Phase Chronic Myeloid Leukemia: Single-Center Experience from India. Blood 2024; 144 (Supplement 1): 6614. doi: https://doi.org/10.1182/blood-2024-210857
• Reshma Benson, Arjun Kachhwaha, Paras Satadeve, Adamya Gupta, Sashi Singh , Kavya Ronanki, Prisla Dalton, Bibhant Shah, Nikhil Nagpal, Uttam Kumar Nath; Treatment Outcomes in Acute Promyelocytic Leukemia Patients Using a Uniform ATRA + ATO Consolidation Therapy Regimen across All Risk Groups: A Single Centre Study from India. Blood 2024; 144 (Supplement 1): 1491. doi: https://doi.org/10.1182/blood-2024-210206
• Rupali Bains, Sudhahar T, Manisha Naithani, Anamika Bakliwal, Karthik Kumar, Paras Satadeve, Adamya Gupta, Kiran Meena, Anissa Atif Mirza, Harish Chandra, Yogesh Bahurupi, Uttam Kumar Nath, Karthik Jayalingappa, Prisla Dalton, Sashi Singh, Kavya Ronanki, Mukesh Mamgain ; Cytokine Behavior and Its Clinical Impact in Chronic Lymphocytic Leukemia: A Real-Time Study in India. Blood 2024; 144 (Supplement 1): 6781. doi: https://doi.org/10.1182/blood-2024-209912
• Kumar, K., Singh, S.K., Nayak, J. et al. Outcome of Childhood and Adolescents and Young Adults ALL Treated with ALL IC-BFM 2009 Protocol–A Single-Center Experience in India. Indian J Hematol Blood Transfus (2024). https://doi.org/10.1007/s12288-024-01898-5
• Gaurav Dhingra, Karthik Kumar, Sashikant Singh, Neha Singh, Uttam K. Nath, (2024), Tyrosine Kinase Inhibitor-Associated Aplastic Anemia- A Lethal Adverse Effect and its Management Difficulties, International Journal of Clinical Case Reports and Reviews, 19(5); DOI:10.31579/2690-4861/594
• Kumar, Karthik; Singh, Sashi Kant; Nayak, Jhasaketan et al. Hypomethylating agent plus low dose venetoclax – a chemotherapy-free induction of acute myeloid leukemia to achieve complete remission in patients unfit for chemotherapy. HemaSphere 7(S3):p e4532157, August 2023. | DOI: 10.1097/01.HS9.0Kumar, Karthik; Kant Singh, Sashi; Nayak, Jhasaketan et al . Comparison of morphological & mrd response with dexamethasone versus prednisolone in BFM 2009 induction therapy in pediatric and aya acute lymphoblastic leukemia: a single-center study from India. HemaSphere 7(S3):p e6867471, August 2023. | DOI: 10.1097/01.HS9.0000968508.68674.71
• Kumar K, Singh S, Nayak J, Dhingra G, Nath UK. Hepatic Plasmacytoma With DEL13q14 Positive on Fluorescent In Situ Hybridization (FISH) on Tissue Biopsy. Cureus. 2022 Dec 31;14(12):e33197. doi: 10.7759/cureus.33197. PMID: 36726881; PMCID: PMC9887231.
• Mamgain G, Naithani M, Patra P, Mamgain M, Morang S, Nayak J, Kumar K, Singh S, Bakliwal A, Rajoreya A, Vaniyath S, Chattopadhyay D, Chetia R, Gupta A, Dhingra G, Sundriyal D, Nath UK. Next-Generation Sequencing Highlights of Diffuse Large B-cell Lymphoma in a Tertiary Care Hospital in North India. Cureus. 2022 Aug 21;14(8):e28241. doi: 10.7759/cureus.28241. PMID: 36158348; PMCID: PMC9489829.
• Nayak J, Kumar K, Singh SK, Dhingra G, Nath UK. A Rare Case of Familial Methemoglobinemia with Congenital Heart Disease. Oman Med J. 2024 May 30;39(3):e634. doi: 10.5001/omj.2024.16. PMID: 39015429; PMCID: PMC11247307 000974448.45321.57